Drug Approval | February 21, 2025
Lupin receives EIR from USFDA for its Somerset manufacturing facility
the inspection conducted from January 27 to January 31, 2025
the inspection conducted from January 27 to January 31, 2025
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
This rating reflects Lupin's leadership in environmental transparency and performance
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Approval is based on positive data from the Phase 3 ECHELON-3 trial
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
Cancer cases in India estimated to reach 1.57 million in 2025
Subscribe To Our Newsletter & Stay Updated
